The New England journal of medicine, 2022-05, Vol.386 (18), p.1721-1731
- Reis, Gilmar
- Silva, Eduardo A.S.M
- Silva, Daniela C.M
- Thabane, Lehana
- Milagres, Aline C
- Ferreira, Thiago S
- dos Santos, Castilho V.Q
- Campos, Vitoria H.S
- Nogueira, Ana M.R
- de Almeida, Ana P.F.G
- Callegari, Eduardo D
- Neto, Adhemar D.F
- Savassi, Leonardo C.M
- Simplicio, Maria I.C
- Ribeiro, Luciene B
- Oliveira, Rosemary
- Harari, Ofir
- Forrest, Jamie I
- Ruton, Hinda
- Sprague, Sheila
- McKay, Paula
- Guo, Christina M
- Rowland-Yeo, Karen
- Guyatt, Gordon H
- Boulware, David R
- Rayner, Craig R
- Mills, Edward J
2022
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Reis, Gilmar
- Silva, Eduardo A.S.M
- Silva, Daniela C.M
- Thabane, Lehana
- Milagres, Aline C
- Ferreira, Thiago S
- dos Santos, Castilho V.Q
- Campos, Vitoria H.S
- Nogueira, Ana M.R
- de Almeida, Ana P.F.G
- Callegari, Eduardo D
- Neto, Adhemar D.F
- Savassi, Leonardo C.M
- Simplicio, Maria I.C
- Ribeiro, Luciene B
- Oliveira, Rosemary
- Harari, Ofir
- Forrest, Jamie I
- Ruton, Hinda
- Sprague, Sheila
- McKay, Paula
- Guo, Christina M
- Rowland-Yeo, Karen
- Guyatt, Gordon H
- Boulware, David R
- Rayner, Craig R
- Mills, Edward J
- Titel
- Effect of Early Treatment with Ivermectin among Patients with Covid-19
- Ist Teil von
- The New England journal of medicine, 2022-05, Vol.386 (18), p.1721-1731
- Ort / Verlag
- United States: Massachusetts Medical Society
- Erscheinungsjahr
- 2022
- Quelle
- MEDLINE
- Beschreibungen/Notizen
- Multiple medications in common use have been considered for the treatment of Covid-19. In this double-blind, randomized, placebo-controlled trial, ivermectin that was administered within 7 days after Covid-19 symptom onset was shown not to be of any clinical benefit.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 0028-4793eISSN: 1533-4406DOI: 10.1056/NEJMoa2115869Titel-ID: cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9006771
- Format
- –
- Schlagworte
- Adult, Ambulatory Care, Anti-Infective Agents - adverse effects, Anti-Infective Agents - therapeutic use, Bayes Theorem, Bayesian analysis, Body weight, Clinical trials, Coronavirus, Coronaviruses, COVID-19, COVID-19 Drug Treatment, Dengue fever, Double-Blind Method, Drug dosages, Emergency medical care, Hospitalization, Humans, Infectious Disease, Ivermectin, Ivermectin - adverse effects, Ivermectin - therapeutic use, Original, Patients, Pharmacists, Placebos, Public health, Quality of life, Risk factors, SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2, Treatment Outcome, Viral Infections, Viruses, West Nile virus